Tenaya Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tenaya released interim data from MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) trials showing improvements in cardiac measures across all evaluable patients, with no dose-limiting toxicities. The company received a $10M upfront payment from Alnylam (eligible for up to $1.1B in milestones) and terminated its manufacturing facility lease, reducing Q2 net loss impact by a $21.8M non-cash impairment charge. Cash of $78.1M is expected to fund operations through Q3 2027.
Why this rating
Positive clinical data and $10M cash boost support pipeline advancement; meaningful relative to $63M market cap. Non-cash charges cloud financials but don't alter cash position fundamentally.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.